31-Dec-2025
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Globe Newswire (Tue, 16-Dec 12:18 PM ET)
Market Chameleon (Fri, 12-Dec 3:36 AM ET)
Globe Newswire (Fri, 12-Dec 7:00 AM ET)
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
Globe Newswire (Mon, 3-Nov 4:05 PM ET)
Globe Newswire (Thu, 30-Oct 4:05 PM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of December 31, 2025, RLAY stock price climbed to $8.46 with 1,943,282 million shares trading.
RLAY has a beta of 1.96, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.24 to the broad based SPY ETF.
RLAY has a market cap of $1.47 billion. This is considered a Small Cap stock.
Last quarter Relay Therapeutics reported $0 in Revenue and -$.43 earnings per share. This fell short of revenue expectation by $-332,000 and missed earnings estimates by -$.02.
In the last 3 years, RLAY traded as high as $23.18 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
RLAY has outperformed the market in the last year with a return of +102.4%, while the SPY ETF gained +17.2%. In the last 3 month period, RLAY beat the market returning +62.1%, while SPY returned +2.7%. However, in the most recent 2 weeks RLAY has underperformed the stock market by returning -0.2%, while SPY returned +0.7%.
RLAY support price is $8.00 and resistance is $8.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.